drugset / Trial / NCT07282093
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
Phase 1
Recruiting
48 enrolled
Ascentage Pharma Group Inc.
Guangzhou Healthquest Pharma Co., Ltd · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label, parallel, single-dose study to evaluate the pharmacokinetic profile of olverembatinib in participants with normal or impaired liver function.
Timeline
- Start
- 2025-11-11
- Primary completion
- 2026-06-30
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olverembatinib | Small molecule | 20 mg | Oral |
Indications
No indication recorded.